Get started
Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

TEVA trade ideas

Teva Pharmaceutical Industries Ltd covic-19 Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need. "We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost," said Brendan O’Grady, Teva Executive Vice President, North America Commercial. "Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately." Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month. Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients. Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.
NYSE:TEVALong
by Bullishcharts
1
Speculative High-Return Idea - LONG "TEVA"I'm not gonna explain the fundamental data of the company for a long time, but I will say briefly that if you look at the dynamics of changes in the company's data, you can see a stable growth of the EPS indicators and a gradual moving towards a positive P&L. It is also indicative that with the huge fall of markets last week, the company did not “fly down” after the market. In the pharmaceutical sector, which itself is risky for investors, TEVA in recent months has shown good growth and the POTENTIAL for the long-term trend to transition from falling to rising. It has already broken up the resistance line lasting from the highest 2015 year point. However, the idea of ​​this post is no longer in long-term investment in this asset, but in speculative buying. The graph clearly shows the divergence of the asset price lows and its RSI and MACD indicators. According to Fibonacci, the stock adjusted to the desired level. Perhaps the fall to the level of 3703 Israeli Shekels and a rebound, or a rebound will be tomorrow. In any case, it is recommended to wait until the RSI fixes above 30 on the 1-hour chart, and then go into the idea. The way out of the idea is at least 4100 Shekels. Stop loss at your discretion, but 3650 is recommended. If you do not have access to the Israeli market, then do not be discouraged, paper is also listed in America under the same name TEVA P.S. It’s up to you to enter long-term or speculate, I recommend speculating only because I myself am a short-term speculator.
TASE:TEVALong
by Eminence-Grise
TEVA Pharma breakout Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results: Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%). Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%). Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B. Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019. Cash flow ops in Q4: $538M (+47%). All components of 2019 outlook met, including spend base reduction target of $3B. 2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B. Source Seeking ALPHA
NYSE:TEVALong
by RedHotStocks